Bodycote PLC (BOY)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 910.00 |
|---|---|
| 52-week range | 585.00 – 967.50 |
| Return, 1 month / 3 months | −3.9% / +30.6% |
| Return, 1 year / 3 years | +42.0% / +78.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 45 |
| Volatility (1 year) | 41.3% |
| Worst drawdown (1 year) | -23.8% |
| Average daily value traded | 1,236.79M GBX |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bodycote PLC is a provider of thermal processing services, offering heat treatment, metal joining and surface technology to manufacturers. Its customers come from aerospace, automotive, energy, medical and general industrial markets, and the company operates a network of processing plants in several countries. Bodycote is based in Macclesfield, England, and its services help improve the strength, durability and performance of metal components used by its industrial clients.
The shares are listed on the London Exchange in UK under the code BOY, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bodycote PLC (BOY) trades on the London Exchange in UK. It last closed at GBX 910.00 on 22 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 191 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.0% and over the last three months it rose 30.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 19.6% | ||
| From 52-week high | -5.3% | ||
| Momentum | 90 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 30.6% | ||
| 6-month return | 34.6% | ||
| 12-month return, skipping the last month | 47.8% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 41.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.8% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 1,236.79M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.1% |
|---|---|
| 1 month | −3.9% |
| 3 months | +30.6% |
| 6 months | +34.6% |
| 1 year | +42.0% |
| 3 years | +78.8% |
| 5 years | +32.6% |
Signals
| 50-day / 200-day average | 920.70 / 760.98 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.18 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Oct 2026 | GBP 0.0720 |
| 30 Apr 2026 | GBP 0.1610 |
| 2 Oct 2025 | GBP 0.0690 |
| 24 Apr 2025 | GBP 0.1610 |
| 3 Oct 2024 | GBP 0.0690 |
| 25 Apr 2024 | GBP 0.1600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.